19.05.2022 06:59:41

Press Release: Addex Announces Participation in the H.C. Wainwright Global Investment Conference

Geneva, Switzerland, May 19, 2022 - Addex https://www.globenewswire.com/Tracker?data=9OQD5G0is-HFNxynkm3c7Gm3dyzKheZJg5S-XONrs7ew_yptxn9xRQUaVP2VCCaC48lNVV6oU4GimD0gnZFzEGc2gTpcaon2kRaucWDb6Po= Therapeutics Ltd https://www.globenewswire.com/Tracker?data=6i_ZDf2MqdaZ5la4hcoU9KUEEBVZgrYQ8ZMy-S0CI3nKDn7AdfeIpilTREQcwuPOBL6IocmXILwHKnOCIIy0tjWQNGnS0Gt1bLxScrBE9do= (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference https://www.globenewswire.com/Tracker?data=kdKFWGMv6MWUxGHFTPQIxOEIbOfgpjgxO2bHO2VcgjABpd0JsOq6FGfSfIlZ_khuFKd52fTLXS5b85vd33rsqf3IZZN2htPdQDkSwH-Fk1v1SBY-USEzS22cOXoM7ljMvXwXardxxNXJUCs33ck2Rw== taking place May 23 - 26, 2022.

Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex. The presentation will be available for viewing on-demand by registered participants.

Mr. Dyer will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact IR@addexpharma.com https://www.globenewswire.com/Tracker?data=DbTfMcDfo6-2UzYgYgtqTyeiRtzmnrSYOYKqtnBfCzwqWKcYfE0lQnvNON2LezFjXXYmabGThyWholf1zRpqCNCtrzDslinp5NYmNNGgxeA=.

About Addex Therapeutics:

Addex Therapeutics https://www.globenewswire.com/Tracker?data=9OQD5G0is-HFNxynkm3c7GfyAL0eMZ47MXZ4nnXkMv3ySsE4G6AIc6is-r2o_UKqyjEq6XF3AXUEqhCh8LaF80pizIkz_DDe1yKLFgIdwQk= is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson's disease levodopa induced dyskinesia (PD-LID) and a Phase 2 clinical study is underway for the treatment of blepharospasm, a form of dystonia. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex's GABAB PAM program for the development of drug candidates with a focus in substance use disorder. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, M4 PAM for psychotic disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

Contacts:

Tim Dyer Mike Sinclair James Carbonara

Chief Executive Officer Partner, Halsin Partners Hayden IR

Telephone: +41 22 884 15 55 +44 (0)20 7318 2955 (646)-755-7412

PR@addextherapeutics.com msinclair@halsin.com james@haydenir.com

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the progress of clinical trials and preclinical studies. The words "may," "will," "could," "would," "should, " "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, as filed with the SEC on March 10, 2022, the final prospectus supplement and accompanying prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

(END) Dow Jones Newswires

May 19, 2022 01:00 ET (05:00 GMT)

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Addex Therapeutics Ltd (spons. ADRs)mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Addex Therapeutics Ltd (spons. ADRs)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Addex Therapeutics Ltd. 1,37 -17,96% Addex Therapeutics Ltd.

Indizes in diesem Artikel

NASDAQ Comp. 19 478,88 -0,06%